drugset / Trial / NCT03096392

Comparison of Hepatic Directed Vesicle (HDV)-Insulin Lispro Versus Insulin Lispro to Further Improve Glycemic Control

NCT03096392

Phase 2 Completed 46 enrolled Diasome Pharmaceuticals Integrium · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Multi-Center, double blind, active comparator controlled multiple dose safety, tolerability and efficacy study

Timeline

Start
2017-04-18
Primary completion
2017-11-15
Completion
2018-03-18

Drugs

EvaluationDrugModalityDoseRoute
Subject HDV Insulin Lispro Protein / enzyme biologic Subcutaneous
Comparator Insulin Lispro Protein / enzyme biologic Subcutaneous